Search results
Is Eli Lilly Stock A Buy Or A Sell As FDA Plans Meeting To Discuss Alzheimer's Drug?
Investor's Business Daily· 1 day agoTrulicity, another diabetes treatment, had $1.46 billion in first-quarter sales, down 26% and below...
Zacks Investment Ideas feature highlights: Eaton, Eli Lilly and Arista Networks
Zacks via Yahoo Finance· 15 hours agoRevenue throughout the period grew 26% year-over-year, driven by strong demand within Mounjaro,...
Fred L. Goldenberg: Medicare 2025 starting to bloom
The Record-Eagle, Traverse City, Mich. via Yahoo News· 5 days agoMay 5—Over the last few weeks, I've been involved in several meetings, both in-person and online, regarding anticipated changes to Medicare and supplemental programs for 2025. As information ...
This Is What Whales Are Betting On Eli Lilly and Co - Eli Lilly and Co (NYSE:LLY)
Benzinga· 4 days agoLilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. Eli Lilly ...
Eli Lilly and Company (NYSE:LLY) Trading 2.6% Higher After Strong Earnings
ETF DAILY NEWS· 4 days agoEli Lilly and Company (NYSE:LLY – Get Free Report) shares rose 2.6% during trading on Monday following a stronger than expected earnings report. Eli Lilly and Company had a return on equity ...
Eli Lilly and Company (LLY) to Issue Quarterly Dividend of $1.30 on June 10th
ETF DAILY NEWS· 3 days agoEli Lilly and Company (NYSE:LLY – Get Free Report) announced a quarterly dividend on Monday, May 6th, RTT News reports. Eli Lilly and Company has raised its dividend payment by an average of ...
Eli Lilly and Company (NYSE:LLY) Price Target Raised to $900.00
ETF DAILY NEWS· 7 days agoEli Lilly and Company (NYSE:LLY – Free Report) had its price objective upped by JPMorgan Chase & Co. from $850.00 to $900.00 in a report published on Wednesday morning, Benzinga reports. The ...
Truist Financial Raises Eli Lilly and Company (NYSE:LLY) Price Target to $892.00
ETF DAILY NEWS· 7 days agoEli Lilly and Company (NYSE:LLY – Free Report) had its price target boosted by Truist Financial from $850.00 to $892.00 in a report released on Wednesday, Benzinga reports. The brokerage currently ...